Kestra Medical stockholder plans $97.9K sale
Kestra Medical Technologies, Ltd. (KMTS) stockholder Jeffrey Lawrence Schwartz filed a notice of proposed sale under Rule 144 for 3,890 common shares of KMTS through Merrill Lynch.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Kestra Medical Technologies, Ltd. (KMTS) stockholder Jeffrey Lawrence Schwartz filed a notice of proposed sale under Rule 144 for 3,890 common shares of KMTS through Merrill Lynch. The shares were acquired on September 4, 2026 via vesting of a restricted stock unit award granted under the issuer’s equity compensation plan.
The proposed sale is tied to an aggregate market value of approximately $97,944.47. KMTS had 58,602,497 common shares outstanding as of the date referenced in the notice, which serves as context for the relative size of this planned disposition.
Key Figures
Key Terms
Rule 144 regulatory
restricted stock unit financial
equity compensation plan financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What does the Form 144 filing disclose for KMTS?
AI-generated analysis. How Rhea-AI works. Not financial advice.